LASN01
Based on 1 Customer Validation
LASN01 is a humanized antibody targeting IL-11R, with a Kd of 37 pM. LASN01 blocks the IL-11 signaling pathway via IL-11Rα, and inhibits the phosphorylation of STAT3 and ERK, as well as the expression of pro-inflammatory cytokines, hyaluronic acid, procollagen and fibrotic markers. LASN01 can be used in studies related to thyroid eye disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.96%
- Molecular Weight:144.19 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG1 kappa
Human
IL-11RA
LASN01 (0.001-100 nM; 1 h) inhibits IL-11-induced activation of pSTAT3 and pERK in DLD-1 cells, with IC50 values of 0.4 nM and 0.1 nM, respectively[1].
LASN01 (1-10 µg/mL; 1 h) inhibits the phosphorylation of STAT3, ERK and AKT induced by IL-11 as well as by IL-11+IGF-1 in orbital fibroblasts derived from TED patients[1].
LASN01 (0.003-10 µg/mL; 97 h) inhibits IL-11-induced hyaluronic acid (HA) release in orbital fibroblasts derived from patients with TED, with an IC50 of 50 ng/mL[1].
LASN01 (3 µg/mL; 97 h) inhibits the release of proinflammatory cytokines (including IL-6 and CCL2) induced by IL-11+IGF-1 in orbital fibroblasts derived from patients with TED[1].
LASN01 (3 µg/mL; 97 h) inhibits the release of type I procollagen in orbital fibroblasts derived from patients with thyroid-associated ophthalmopathy (TED) induced by TGFβ[1].
LASN01 (1-10 µg/mL; 6-48 h) modulates IL-11-induced and IL-11+IGF-1-induced gene expression in orbital fibroblasts derived from patients with thyroid-associated ophthalmopathy (TED), and specifically inhibits pathways related to inflammation, cytokine signaling and fibrosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DLD-1 human colorectal adenocarcinoma cells
-
Concentration:0.001, 0.1, 1, 10 and 100 nM
-
Incubation Time:30 min (pre-incubation); 30 min (IL-11 stimulation)
-
Result:Potently inhibited IL-11-induced pSTAT3 activation with an IC50 of 0.4 nM.
Potently inhibited IL-11-induced pERK activation with an IC50 of 0.1 nM.
-
Cell Line:thyroid eye disease (TED) patient-derived orbital fibroblasts
-
Concentration:3 µg/mL
-
Incubation Time:1 h (pre-incubation); 96 h (IL-11+IGF-1 stimulation)
-
Result:Significantly reduced HA release induced by the combination of IL-11 and IGF-1 to levels comparable to teprotumumab.
Further reduced HA release to near baseline levels when combined with teprotumumab.\nExhibited broad inhibition of multiple pro-inflammatory mediators.
Significantly reduced IL-6 and CCL2 release induced by IL-11 + IGF-1.
-
Cell Line:thyroid eye disease (TED) patient-derived orbital fibroblasts
-
Concentration:3 µg/mL
-
Incubation Time:1 h (pre-incubation); 96 h (TGFβ stimulation)
-
Result:Significantly reduced TGFβ-induced procollagen I release from TED orbital fibroblasts.
-
Cell Line:thyroid eye disease (TED) patient-derived orbital fibroblasts
-
Concentration:1, 3 and 10 µg/mL
-
Incubation Time:48 h (qRT-PCR; co-incubated with IL-11+IGF-1); 6-48 h (RNAseq; co-incubated with IL-11 or IL-11+IGF-1)
-
Result:Downregulated 522 IL-11-induced genes at 6 hours and 95 IL-11-induced genes at 48 hours, including fibroinflammatory and extracellular matrix-related genes such as HAS2, C3, C4B, APLNR, and CHI3L1.
Downregulated 539 genes at 6 hours and 845 genes at 48 hours under IL-11+IGF-1 stimulation.
Reduced IL-11+IGF-1-induced expression of HAS2, IL-6, and CCL2 mRNA as confirmed by qRT-PCR.
Primarily inhibited pathways linked to inflammation, cytokine signaling, glycosaminoglycan production, and fibrosis as shown by gene ontology analysis.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Molecular Weight 144.19 kDa
-
Color Colorless to light yellow
-
SMILES
[LASN01]
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
LASN01 Related Classifications
HY-P991487 Related Classifications
Powered by Bioz